SUO 2023 Bladder Cancer

Viewing 1-12 of 12 articles

SUO 2023: Optimizing Care for Women: Gynecologic Considerations for the Urologic Oncologist

SUO 2023: Long-term Outcomes of Bladder-Sparing Therapy Compared to Upfront Radical Cystectomy in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in an International Cohort

SUO 2023: Primary Chemoablation for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer: The ENVISION Trial

SUO 2023: First Results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC

SUO 2023: Treatment of Low-grade, Intermediate-risk Non-muscle Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) compared to TURBT Monotherapy: The Phase 3 ATLAS Trial

SUO 2023: Marker Lesion Study of Oral Erdafitinib in Patients With Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With FGFR3/2 Alterations in THOR-2: Updated Cohort 3 Results

SUO 2023: Comparing White Light versus Blue Light Cystoscopy Recurrence Outcomes Among Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting: A Propensity-scored Matched Analysis

SUO 2023: Efficacy of Intravesical Nadofaragene Firadenovec-vcng for Patients with Bacillus Calmette-Guerin-Unresponsive Carcinoma in Situ of the Bladder: 36-Month Follow-Up from a Phase 3 Trial

SUO 2023: Updated Efficacy and Safety of Oral Erdafitinib in Patients With Bacillus Calmette–Guérin-Unresponsive, High-Risk, Non–Muscle-Invasive Bladder Cancer With FGFR3/2 Alterations in THOR-2 Cohort 2

SUO 2023: Bladder Cancer Debate for MIBC: Trimodality Therapy/Radiotherapy after Complete Clinical Response

SUO 2023: Bladder Cancer Debate for MIBC: Neoadjuvant Chemotherapy Followed by Surveillance if Complete Clinical Response

SUO 2023: Bladder Cancer Debate for MIBC: Radical Cystectomy SHOULD be Performed after Achieving cT0 after Neoadjuvant Chemotherapy